Phase 2/3 Study for the Evaluation of Safety and Efficacy of HAV for Vascular Reconstruction in Patients With Limb- or Life-threatening Vascular Trauma

Overview of attention for article published in Journal of Vascular Surgery, April 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 1 news story.

March 22, 2024 Humacyte, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.